Goldman on Intellia Therapeutics (NTLA): 'While shares are trading higher after the news, safety could remain an overhang given the specific risk factors'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $8.00 price target on Intellia Therapeutics (NASDAQ: NTLA)THe analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
